Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients

British Journal of Clinical Pharmacology

Volumn 65, Issue SUPPL. 1, 2008, Pages 86-94

  Rosario, Maria C ^a   Jacqmin, Philippe ^b   Dorr, Pat ^c   James, Ian ^c   Jenkins, Timothy M ^c   Abel, Samantha ^c   Van Der Ryst, Elna ^c  

^a PFIZER INC   (United States)

^b Exprimo NV   (Belgium)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

CCR5; Maraviroc; NONMEM; Population pharmacodynamic meta analysis

Indexed keywords

CHEMOKINE RECEPTOR CCR5; MARAVIROC; PLACEBO;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IN VIVO STUDY; INHIBITION KINETICS; NORMAL HUMAN; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR OCCUPANCY; SIMULATION; VIRUS INHIBITION; VIRUS LOAD;

ANTI-HIV AGENTS; COMPUTER SIMULATION; CYCLOHEXANES; HIV INFECTIONS; HUMANS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, CCR5; TRIAZOLES; VIRAL LOAD;

EID: 40549098400     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03140.x     Document Type: Article

References (10)

1. Fatkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI, Saag MS, Goebel FD, Rockstroh JK, Dezube BJ, Jenkins TM, Medhurst C, Sullivan JF, Ridgway C, Abel S, Youle M, van der Ryst E. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005 11 : 1170 2.
2. Dorr PK, Dobbs S, Rickett G, Lewis B, Macartney M, Westby M, Perros M. In vitro evaluation of prolonged CCR5 occupancy by small molecule antagonists with anti-HIV activity. Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother 2003 43 : F 1462.
3. Pullen S, Sale H, Napier C, Mansfield R, Holbrook M. Maraviroc is a slowly reversible antagonist at the human CCR5 in a CRE luciferase reporter gene assay (abstract 504). In : 13th Conference on Retroviruses and Opportunistic Infections. 2006 February 5-8; Denver, CO.
4. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C, Webster R, Armour D, Price D, Stammen B, Wood A, Perros M. Maraviroc (UK-427 8 57), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005 49 : 4721 32.
5. Dorr P, Macartney M, Rickett G, Smith-Burchnell C, Dobbs S, Mori J, Griffen P, Lok J, Irvine R, Westby M, Hitchcock C, Stammen B, Price D, Armour D, Wood A, Perros M. UK-427 8 57, a novel small molecule HIV entry inhibitor is a specific antagonist of the chemokine receptor CCR5 (abstract 12). In : 10th Conference on Retroviruses and Opportunistic Infections. 2003 February 10-14; Boston, MA.
6. Rosario MC, Jacqmin P, Dorr P, van der Ryst E, Hitchcock C. A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc. Clin Pharmacol Ther 2005 78 : 508 19.
7. Rosario MC, Poland B, Sullivan J, Westby M, van der Ryst E. A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc. J Acquir Immune Defic Syndr 2006 42 : 183 91.
8. Beal SL, Sheiner LB. NONMEM User's Guide. San Francisco, CA : NONMEM Project Group, 1992.
9. Chan PLS, Weatherley B, McFadyen L. A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infect subjects. Br J Clin Pharmacol 2008 65 (Suppl. 1 76 85.
10. Jacqmin P, McFadyen L, Wade JR. A receptor theory-based semi-mechanistic PD model for the CCR5 noncompetitive antagonist maraviroc. Br J Clin Pharmacol 2008 65 (Suppl. 1 95 106.